Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA, Cenix Ink miRNA Deal

NEW YORK (GenomeWeb News) – Dutch firm InteRNA Technologies and German firm Cenix BioScience today said that they will collaborate on screening assays for miRNAs and therapeutic targets for cancer.
 
Cenix will use InteRNA’s lentiviral-based miRNA overexpression library in high-throughput screening assays in combination with high-content, multi-parametric phenotypic analyses to determine the biological role of individual miRNAs and to identify cancer drug targets.
 
“Cenix’s unique expertise on small RNA-based high-throughput screening and phenotypic analyses will be instrumental in our discovery programs”, Roel Schaapveld, chief operating officer of InteRNA Technologies, said in a statement.
 
Financial and other terms of the collaboration were not disclosed.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.